SP-26 is a ketamine-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia. Final safety and absorption data is expected in March 2025. Learn more about the pharmacokinetic, safety and tolerability study of SP-26: https://bit.ly/3QeLeVA #ClinicalStudy #Fibromyalgia #Therapeutics #ChronicPain #Biopharma
Silo Pharma Inc.
Pharmaceutical Manufacturing
Englewood Cliffs, NJ 638 followers
Silo Pharma (Nasdaq: SILO) is a biopharma company focused on merging traditional therapeutics with psychedelic research.
About us
Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder, fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.
- Website
-
https://silopharma.com/
External link for Silo Pharma Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Englewood Cliffs, NJ
- Type
- Public Company
Locations
-
Primary
Get directions
560 Sylvan Ave
Suite 3160
Englewood Cliffs, NJ 07632, US
Updates
-
Stay ahead! Sign up to get updates, information and news about Silo Pharma. Subscribe to email alerts here: https://bit.ly/3J5RhrV #Biopharma
-
-
The provisional patent filing for Silo’s PTSD treatment adds to Silo’s growing portfolio of pending patents for SPC-15 technology, originally licensed through a collaboration with Columbia University. This exclusive agreement enables Silo to develop, manufacture, and commercialize SPC-15 globally. Learn more about the patent application here: https://bit.ly/3CmzvRz #Biopharma #PTSD #USPatent #PyschiatricDisorders #Anxiety #Neuroscience #Neurology
-
Silo Pharma Secures New Patent for PTSD Treatment. The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting #PTSD. Read more via Pharma Now - Empowering Pharma Leadership: https://bit.ly/41Brzpe #ClinicalTrial #USPatent #Biopharma
-
Silo CEO Eric Weisblum comments on granted U.S. patent for novel intranasal post-traumatic stress disorder treatment, “Strategic IP and patent expansion is key to advancing our lead asset SPC-15 to clinical trials and creating value for our full pipeline of novel assets. This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15.” Read more: https://lnkd.in/g6xE3S6U #Biotech #Biopharma #Science #ClinicalResearch #Biotechnology #ClinicalTrial #PTSD #MedicalResearch
-
-
The launch of the non-GLP study in December 2024 marked the first small animal testing of SP-26, a key preclinical milestone. Implantation (dosing) was completed in the first week of January 2025, and no animals experienced serious side effects or discomfort. Read more about Silo’s ongoing study for SP-26 here: https://bit.ly/3QeLeVA #ClinicalStudy #ChronicPain #Fibromyalgia #Therapeutics
-
Yesterday, Silo announced that the USPTO issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder. The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in November 2022. In case you missed it, dive into the press release: https://bit.ly/3QzJQNy #PTSD #Stress #Biopharma #Pharma #Biotech #Biotechnology #Pharmacology #ClinicalTrial
-
-
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment. Read the press release here: https://bit.ly/3QzJQNy #USPatent #Biopharma #PTSD #ClinicalTrial #MedicalResearch
-
ln addition to SP-26, Silo is gaining momentum along its path to first-in-human trials for SPC-15, an intranasal prophylactic targeting PTSD and stress-induced anxiety disorder. A GLP-compliant pharmacokinetic and pharmacodynamic study is in progress, which Silo believes will deliver final data required for an IND application to the FDA. Learn more about SILO’s ongoing study here: https://bit.ly/3QeLeVA #ClinicalStudy #ChronicPain #Fibromyalgia #Therapeutics
-
CEO Eric Weisblum shares insight on the recent announcement of a provisional patent application for our lead asset SPC-15: “We believe that the SPC-15 combination treatment is showing promise in multiple stress-induced behaviors and disorders. This provisional patent application, if approved and the patent issued, will augment and expand the existing patents on this technology which we originally acquired through our global license agreement.” Read more: https://bit.ly/434BuVB #USPatent #PTSD #Biopharma #Science #Neuroscience #Pharma #ScienceNews #MedicalResearch #ProvisionalPatent
-